World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
36890
World Ranking
11173
National Ranking
5748

Jason Gotlib publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jason Gotlib sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 531 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jason Gotlib D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jason Gotlib sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jason Gotlib is affiliated with Stanford University in the United States and has contributed extensively to the fields of Medicine, Immunology, and Microbiology. They have published over 400 academic works, with significant focus on Genetics, Immunology, Rheumatology, Hematology, and Physiology as subfields.

Gotlib's research primarily concentrates on several key topics within medical science, including:

  • Mast cells and histamine
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Urticaria and Related Conditions
  • Asthma and respiratory diseases

The scientist has authored papers in a range of high-impact journals, with frequent publications in:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Allergy and Clinical Immunology
  • The Journal of Allergy and Clinical Immunology In Practice
  • Blood Advances

Recent notable publications include:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data (2022, Blood)
  • Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal (2021, HemaSphere)
  • Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology (2020, Journal of the National Comprehensive Cancer Network)
  • Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts (2020, Theranostics)
  • World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management (2021, American Journal of Hematology)

Collaborations are a significant aspect of Gotlib's work, with frequent co-authors including:

  • Tracy I. George
  • Deepti Radia
  • Daniel J. DeAngelo
  • Karin Hartmann
  • Andreas Reiter

Best Publications

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • Granulocyte-Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML

    Catriona H M Jamieson;Laurie E Ailles;Scott J Dylla;Manja Muijtjens

  • Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

    Peter Valent;Amy D. Klion;Hans-Peter Horny;Florence Roufosse

  • Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML

    Julia E. Maxson;Jason Gotlib;Daniel A. Pollyea;Angela G. Fleischman

  • Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis

    Mignon L. Loh;Shashaank Vattikuti;Suzanne Schubbert;Melissa G. Reynolds

  • Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

    Jason Gotlib;Hanneke C. Kluin-Nelemans;Tracy I. George;Cem Akin

  • Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

    Animesh Pardanani;Jason R. Gotlib;Catriona Jamieson;Jorge E. Cortes

  • Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

    G. Barosi;R. A. Mesa;J. Thiele;F. Cervantes

  • Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    Ayalew Tefferi;Francisco Cervantes;Ruben Mesa;Francesco Passamonti

  • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

    Ruben A. Mesa;Srdan Verstovsek;Francisco Cervantes;Giovanni Barosi

  • Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms

    Stephen T. Oh;Erin F. Simonds;Carol Jones;Matthew B. Hale

  • Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology

    Karin Hartmann;Luis Escribano;Clive Grattan;Knut Brockow

  • Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

    Srdan Verstovsek;Ruben A Mesa;Jason R Gotlib;Vikas Gupta

  • The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

    Jason Gotlib;Jason Gotlib;Jason Gotlib;Jan Cools;Jan Cools;Jan Cools;James M. Malone;James M. Malone;James M. Malone;Stanley L. Schrier;Stanley L. Schrier;Stanley L. Schrier

  • The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

    Catriona H. M. Jamieson;Jason Gotlib;Jeffrey A. Durocher;Mark P. Chao

  • Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

    Jason Gotlib;Caroline Berubé;Joseph D. Growney;Ching Cheng Chen

  • A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

    F Passamonti;T Giorgino;B Mora;P Guglielmelli

  • Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

    John Mascarenhas;Ronald Hoffman;Moshe Talpaz;Aaron T. Gerds

  • NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

    O'Brien S;Berman E;Borghaei H;Deangelo Dj

Frequent Co-Authors

Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Peter Valent
Peter Valent Medical University of Vienna
Michael W. Deininger
Michael W. Deininger University of Utah
Andreas Reiter
Andreas Reiter Heidelberg University
Karin Hartmann
Karin Hartmann University Hospital of Basel
Vikas Gupta
Vikas Gupta Princess Margaret Cancer Centre
Cem Akin
Cem Akin University of Michigan–Ann Arbor
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Richard T. Silver
Richard T. Silver Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medicine but seeking flexible learning options, there are a variety of online health degree pathways to consider. A popular choice is pursuing a nursing degree online, which can open doors to a rewarding career in patient care. These programs allow students to balance work and study, making them ideal for busy professionals or career changers.

For registered nurses aiming to advance, the cheapest accredited online rn to bsn programs offer an accessible route to earning a bachelor’s degree. Additionally, those aspiring to leadership, research, or teaching roles in nursing can benefit from online phd programs in nursing, providing advanced knowledge and skills at the doctoral level.

If you hold a non-nursing bachelor’s degree and want to enter the nursing field quickly, msn direct entry programs online may be the right fit. These accelerated programs prepare students for licensure and graduate-level nursing roles, expanding career opportunities within the healthcare sector.

Best Scientists Citing Jason Gotlib

Trending Scientists